|
|
202, 279 Midpark Way SE
Calgary, Alberta T2X 1M2 USA
phone:403.254.9252
fax:403.256.8495
|
|
| Symbol |
RVX |
| Exchange |
TSX |
| Founded |
0 |
| Employees |
|
|
|
| www.resverlogix.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Discovery and development of biopharmaceuticals. |
|
| Management |
| Donald J. Mccaffrey, President And Ceo, Co-Founder; Norman C.W. Wong, M.D., Frcp, Chief Scientific Officer & Co-Founder; A. Brad Cann, Ca, Chief Financial Officer; Jan O. Johansson, M.D., Ph.D., Senior Vice President Medical Affairs; Kenneth Lebioda, Ba, Senior Vp Business & Corporate Development |
| |
|
|
|
|
|
|
|
| Keywords |
| small moleculre, cardiovascular disease, cholesterol, cancer, oncology |
|
|
|
| Description |
|
Resverlogix Corporation is a Canadian biotechnology company engaged in the discovery and development of biopharmaceuticals. Resverlogix's NEXVASo Program applies advanced medical research to develop therapies that increase high-density lipoprotein (HDL), the "good cholesterol," to treat cardiovascular diseases. The TGF-beta Shield� Program utilizes an immunomodulating therapy to target cancers and fibrotic diseases. |
|
| Technology / Differentiation |
| The NEXVASo program focuses on the discovery and development of novel small molecules to treat cardiovascular disease, the leading cause of death in industrialized countries. Resverlogix is developing several classes of molecules that increase Apolipoprotein AI (ApoAI), the major component of High Density Lipoprotein (HDL), the "good cholesterol". HDL plays a critical role in preventing CVD progression and enhancing CVD regression by increasing Reverse Cholesterol Transport (RCT), the mechanism through which cholesterol is removed from the body. Published research indicates that the ability to increase ApoAI is a key element to improving abnormal lipid profiles, a major modifiable factor in CVD. In addition the NEXVAS? bioassay is a platform technology used to screen compounds that regulate ApoAI. This technology has been instrumental in the development of the CVD small molecule program. The TGF-Beta Shield? program is developing an immunomodulating approach to antagonize Transforming Growth Factor-beta (TGF-b) to treat cancers and fibrotic diseases. TGF-Beta Shield? Oncology is developing a therapeutic agent that enhances the body's ability to launch natural immune response against cancer. Resverlogix's oncology program is completing animal model studies to prepare the technology for clinical testing. In addition Resverlogix is adapting the TGF-Beta Shield? Oncology technology to treat fibrotic diseases. Resverlogix is moving this technology platform through preclinical testing to produce effective novel therapies for the prevention and reduction of fibrotic damage in organs such as the eye, heart, kidney, lung and liver. |
|
|
| Strategy |
Resverlogix operates under a business model in which it positions itself as a research and development enterprise focused on the development of novel technologies for important medical markets with unmet needs. Resverlogix is pursuing licensing opportunities and alliance partners that are best suited to bring these technology platforms to successful end stage market use.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
